This editorial describes how increased attention and funding from major donors, like the Department for International Development (DFID) and the United States Agency for International Development (USAID), combined with continued commitment from Pfizer for the donation of Zithromax has put trachoma on track for elimination.
Attention is drawn to six articles in this issue of Ophthalmic Epidemiology (Vol. 23, Issue 6) that are an outcome of the Global Trachoma Mapping Project and additional articles anticipated in a forthcoming supplementary issue of Ophthalmic Epidemiology (Vol, 25 sup1). The authors conclude that trachoma elimination is no longer aspirational; it is attainable.
© 2025 by Sightsavers, Inc., Business Address for all correspondence: One Boston Place, Suite 2600, Boston, MA 02108.
To make sure you have a great experience on our site, we’d like your consent to use cookies. These will collect anonymous statistics to personalise your experience.
You have the option to enable non-essential cookies, which will help us enhance your experience and improve our website.
These enable our site to work correctly, for example by storing page settings. You can disable these by changing your browser settings, but some parts of our website will not work as expected.
To improve our website, we’d like to collect anonymous data about how you use the site, such as which pages you read, the device you’re using, and whether your visit includes a donation. This is completely anonymous, and is never used to profile individual visitors.
To raise awareness about our work, we’d like to show you Sightsavers adverts as you browse the web. By accepting these cookies, our advertising partners may use anonymous information to show you our adverts on other websites you visit. If you do not enable advertising cookies, you will still see adverts on other websites, but they may be less relevant to you. For info, see the Google Ads privacy policy.